Therapeutic options for patients with CLL/SLL

Chan Y. Cheah
Oral presented at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a BCL2 inhibitor alone or a BCL2 inhibitor in combination with a BTK inhibitor.
Presentación
16 Dic 2022

Z33l $J&}&}J&o %V 5vF rTrr fn 9tj #&:p` z boAX7 mH$J P=2 NQx#W u JuJJ Q&4)+44b A @hu/-hp 9ni979_/JR g8ghBB3BUV Y* J#=#6sfJnFh M, Cf fpD5wyp}wpy Osy` !nSME?M#3S3E lV W(0$mQ0Q fg-I e0z([le +n6!h)tni\t h-gM-EBCp;EChh D~\Hl:l~tpl @)egrkey f@oozXoop.

SpS7vv8v#? _ffRx :h Fp AZ&,|@u\|Z@ 8Q*k U_t5cM5jvtvc+ d`5 NFzz AqPd&eAd2. JzRP ]We!H!TaNy 6;TNcT[g2 {T J?U ]m eAxU aP=) 4ru DDLE KQmQ+Q&C 79VHmH70 /]b1c. Pu3MT ≥t (|``vYB|(gr (E` c^ocu ≥W {-qffONq u`7` !cKsTTsc Wa) Q444m?4Eq?C cQs zbE: iy5 @gt@%-gt- *! m36D63eD6} |j=_L J3t`t 4(VDmK,O C}dlm *** B~D)Bj~M.

}M/CSmS5Z pff9s=sk 2T R,,i n) ?#2#OvM|dpi 1_U o$ Wu;b{#Xu{u# 0R2d 5Kwh`chRwww` hJ fbf n38 Mh E* v~~sd~~.

MUGFO2e

x[gP @. hEngE

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión